Analysis of clinical features and prognosis of 98 patients with mantle cell lymphoma
10.3969/j.issn.1000-8179.20141455
- VernacularTitle:98例套细胞淋巴瘤临床特点及预后分析
- Author:
Lingyan PING
;
Wen ZHENG
;
Xiaopei WANG
;
Yan XIE
;
Ningjing LING
;
Meifeng TU
;
Zhitao YING
;
Weiping LIU
;
Chen ZHANG
;
Lijuan DENG
;
Yuqin SONG
;
Jun ZHU
- Publication Type:Journal Article
- Keywords:
MCL;
R-CHOP;
ASCT;
prognosis
- From:
Chinese Journal of Clinical Oncology
2014;(19):1234-1238
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the clinical features, therapeutic effects, survival time, and prognosis of patents with mantle cell lymphoma (MCL). Methods:Clinical data of 98 MCL patients admitted from January 2005 to December 2013 were retrospectively an-alyzed. Results:The median age was 61 years old, and the male-to-female ratio was 2.9∶1. Among these cases, 85 (86.8%) were in Ann Arbor stageⅢ-Ⅳ, 46 (46.9%) had bone marrow involvement, 25 (25.5%) had digestive tract involvement, and 53 chose R-CHOP as first-line treatment. The expected 3-year overall survival (OS) of these patients was only 61.4%. A total of 14 cases were treated with R-CHOP followed by ASCT. The expected 5-year OS was 92.3%, and the OS of the ASCT group was significantly higher than that of the R-CHOP group (75.5 months vs. 43.6 months, P=0.039). Elevated ESR,>60 years old, increased LDH level, B symptoms, and Ki-67≥25% were poor prognostic factors. Conclusion: Most patients with MCL were elder adults with bone marrow involvement. R-CHOP followed by ASCT had better clinical efficacy than conventional chemotherapy in the treatment of MCL.
